All In Biotech

Free tool

Drugs in development

Investigational drugs and biologics in industry-sponsored Phase 2 and Phase 3 trials that are active or finished in the last two years, and that FDA has not approved. Built from 10,322 ClinicalTrials.gov records, with code names and generic names merged. For approved drugs, use Drug Search.

Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations

Drugs in development

3,685

Not FDA-approved

In Phase 3

1,424

Highest phase reached

Matching your filters

1,268

Reset

1,268 drugs in development

Names, sponsors and conditions come from the trial records. Click a drug for its trials.

  • SHR-1681Phase 21 trial

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Malignant Solid Tumors

  • SHR-2017Phase 21 trial

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · For Prevention of Bone Events in Patients With Bone Metastases From Solid Tumors

  • SHR-3276Phase 21 trial

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors

  • SHR-4298Phase 21 trial

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Malignant Solid Tumors

  • SHR-4394Phase 21 trial

    Jiangsu HengRui Medicine Co., Ltd. · Prostate Cancer

  • SHR-4602Phase 21 trial

    Shanghai Hengrui Pharmaceutical Co., Ltd. · Advanced Solid Tumors

  • SHR-4642Phase 21 trial

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors

  • SHR-7367Phase 21 trial

    Shanghai Hengrui Pharmaceutical Co., Ltd. · Solid Tumor

  • SHR-8203Phase 21 trial

    Beijing Suncadia Pharmaceuticals Co., Ltd · Solid Tumors

  • SHR-9803Phase 21 trial

    Jiangsu HengRui Medicine Co., Ltd. · Advanced Solid Tumors

  • SHR3680Phase 21 trial

    Jiangsu HengRui Medicine Co., Ltd. · Prostate Cancer

  • SKB105Phase 21 trial

    Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Advanced Solid Tumors

  • SKB315Phase 21 trial

    Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Gastroesophageal Junction Adenocarcinoma

  • SKB565Phase 21 trial

    Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Advanced Solid Tumors

  • SL-28Phase 21 trial

    Second Life Therapeutics · Head & Neck Cancer, Pancreas Carcinoma, Pancreas Cancer, Metastatic

  • SMP-656Phase 21 trial

    Chengdu SciMount Pharmatech Co., Ltd. · HER2-positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC)

  • SMP3124LPPhase 21 trial

    Sumitomo Pharma America, Inc. · Solid Tumor

  • SNB-101Phase 21 trial

    SN BioScience · Patient is Not Suitable for Complete Surgical Resection With a Cytologically or Histologically Confirmed Small Cell Lung Cancer(SCLC)

  • SNS-101anti-VISTAPhase 21 trial

    Sensei Biotherapeutics, Inc. · Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer

  • SNV4818Phase 21 trial

    Pikavation Therapeutics, Inc. · Advanced Solid Tumors

  • SOA101Phase 21 trial

    Shine-On Biomedical Co., Ltd. · Solid Tumors

  • SOT106Phase 21 trial

    SOTIO Biotech a.s. · Osteosarcoma Metastatic, Soft Tissue Sarcoma (STS), Osteosarcoma, Advanced

  • SOT109Phase 21 trial

    SOTIO Biotech a.s. · Colorectal Cancer (Locally Advanced or Metastatic)

  • SotevtamabAB-16B5Phase 21 trial

    Alethia Biotherapeutics · Metastatic Colorectal Cancer

  • SP-002Phase 21 trial

    Stamford Pharmaceuticals, Inc. · Basal Cell Carcinoma

  • SPH5030Phase 21 trial

    Shanghai Pharmaceuticals Holding Co., Ltd · Biliary Tract or Colorectal Cancer With Her2-positive/Mutated

  • SRP1020Phase 21 trial

    Shanghai SciBrunch Therapeutics Co., Ltd. · Advanced Solid Tumors, PARP Inhibitor

  • ST-067Phase 21 trial

    Simcha IL-18, Inc. · Cancer, Solid Tumor, Melanoma

  • ST101Phase 21 trial

    Sapience Therapeutics · Glioblastoma, Melanoma Stage IV, Breast Cancer

  • STC-1010Phase 21 trial

    Brenus Pharma · Unresectable Metastatic Colorectal Cancer, Unresectable Locally Advanced Colorectal Cancer

  • STC-15Phase 21 trial

    STORM Therapeutics LTD · Solid Tumor, Sarcoma, Leiomyosarcoma

  • STK-012Phase 21 trial

    Synthekine · Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC

  • STM-416Phase 21 trial

    SURGE Therapeutics · Non-muscle-invasive Bladder Cancer

  • STRO-002Phase 21 trial

    Tasly Pharmaceutical Group Co., Ltd · Neoplasm Malignant

  • STX-001Phase 21 trial

    Strand Therapeutics Inc. · Advanced Solid Tumor

  • STX-003Phase 21 trial

    Strand Therapeutics Inc. · Advanced Solid Tumor

  • STX-241PFL-241Phase 21 trial

    Pierre Fabre Medicament · Non-small Cell Lung Cancer (NSCLC)

  • STX-721PFL-721, EscalatedPhase 21 trial

    Pierre Fabre Medicament · Non-Small Cell Lung Cancer, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation

  • SV-102Phase 21 trial

    Syncromune, Inc. · Metastatic Castration-resistant Prostate Cancer

  • SX-682Phase 21 trial

    Syntrix Biosystems, Inc. · Metastatic Castration-resistant Prostate Cancer

  • SYHX2011Phase 21 trial

    CSPC Ouyi Pharmaceutical Co., Ltd. · Advanced Breast Cancer

  • SYS6006Phase 21 trial

    CSPC Megalith Biopharmaceutical Co.,Ltd. · Advanced Solid Tumors

  • SYS6023Phase 21 trial

    CSPC Megalith Biopharmaceutical Co.,Ltd. · Advanced Breast Cancer

  • SYS6045Phase 21 trial

    CSPC Megalith Biopharmaceutical Co.,Ltd. · Advanced Solid Tumors

  • SYS6062Phase 21 trial

    CSPC Megalith Biopharmaceutical Co.,Ltd. · Advanced Solid Tumors, Gastric Cancer (GC), Colorectal Cancer (CRC)

  • SYS6088Phase 21 trial

    CSPC Megalith Biopharmaceutical Co.,Ltd. · Advanced/Metastatic Solid Tumors

  • TagmokitugPhase 21 trial

    Coherus Oncology, Inc. · Solid Tumor

  • TAK-188Phase 21 trial

    Takeda · Advanced or Metastatic Solid Tumors

  • TAK-505Phase 21 trial

    Takeda · Malignant Solid Tumors

  • TAS0953HM06Phase 21 trial

    Taiho Pharmaceutical Co., Ltd. · RET-altered Non Small Cell Lung Cancer, RET-altered Solid Tumors

NewerPage 24 of 26Older

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.